Jakarta, CNBC Indonesia – There’s good news about vaccines Covid-19 concoction of the company from the United States (US) Johnson & Johnson. Preliminary results from phase 2 clinical trials indicate that this vaccine is well tolerated. Even one dose appears to produce a strong immune response in nearly all of the 800 people.
The trial included two age groups: 18-55 years and 65 years and over, and looked at the safety and side effects of two different doses. The preliminary findings from the trials show that the vaccine actually triggers an immune response and is safe to proceed to large-scale trials.
The study was posted on MedRxiv, but has not been reviewed or published in a medical journal. The researchers found that 99% of the participants aged 18 to 55 in both dose groups had developed antibodies to the virus 29 days after being vaccinated.
The analysis found that most of the side effects, such as fever, headache, fatigue, body aches, and pain at the injection site, were mild and went away after a few days.
Some participants will receive a second shot of the vaccine as part of a trial. The Ad26.COV2.S vaccine uses the same technology used for Johnson & Johnson’s vaccines in the treatment of Ebola, Zika, HIV and RSV.
Phase 3 trials will examine the safety and effectiveness of a single dose against a placebo for preventing Covid-19 symptoms. Johnson & Johnson said it plans to enroll 60,000 adult volunteers at more than 200 locations in the US and other countries around the world.
The fact that the trial will examine the efficacy of one dose of vaccine, not two doses, should speed up results, according to Dr. Paul Stoffels as Chief Scientific Officer of Johnson & Johnson.
So far, this is the only US trial of a Covid-19 phase 3 vaccine that has tested a single-dose vaccine. The company said stricter vaccine guidelines being considered by the US Food and Drug Administration (FDA) could add to the company’s vaccine development schedule.
Meanwhile, Dr. Anthony Fauci, as director of the National Institute of Allergy and Infectious Diseases, said the Covid-19 vaccination could most likely start in November or December. However, normal conditions will only occur in 2021.
“By the time you get enough people vaccinated you can feel like you have had a pretty big impact on the outbreak, so you can start thinking about maybe a little more toward normality, which is very likely, like me and others have. Maybe quarterly. third or so in 2021. Maybe even until the fourth quarter, “he said.
(Friends / friends)
– .
